XNASFHTX
Market cap267mUSD
Dec 27, Last price
4.82USD
1D
-5.30%
1Q
-48.50%
IPO
-71.98%
Name
Foghorn Therapeutics Inc.
Chart & Performance
P/E
—
P/S
7.85
EPS
—
Div Yield, %
0.00%
Shrs. gr., 5y
16.42%
Rev. gr., 5y
0.00%
Revenues
34m
+77.63%
Net income
-98m
L-9.60%
CFO
-118m
L
Earnings
Mar 05, 2025
Profile
Foghorn Therapeutics Inc., a clinical-stage biopharmaceutical company, discovers and develops medicines targeting genetically determined dependencies within the chromatin regulatory system. The company uses its proprietary Gene Traffic Control platform to identify, validate, and potentially drug targets within the system. It is developing FHD-286, a small molecule inhibitor of the enzymatic activity of BRG1 and BRM for the treatment of metastatic uveal melanoma and relapsed and/or refractory acute myeloid leukemia and myelodysplastic syndrome; and FHD-609, a small molecule protein degrader for BRD9 to treat patients with synovial sarcoma. The company is also developing an enzymatic inhibitor and a protein degrader as selective modulators of BRM; and ARID1B selective modulators for the treatment of ovarian, endometrial, colorectal, bladder, and gastric cancers. It has a research collaboration and license agreement with Merck Sharp & Dohme Corp. to discover and develop novel oncology therapeutics against a transcription factor target; and with Loxo Oncology to create novel oncology medicines. Foghorn Therapeutics Inc. was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.
Valuation
Title USD in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|
| 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | |
| Income | ||||||
Revenues | 34,155 77.63% | 19,228 1,357.77% | 1,319 206.74% | |||
Cost of revenue | 251,750 | 136,384 | 109,568 | |||
Unusual Expense (Income) | ||||||
NOPBT | (217,595) | (117,156) | (108,249) | |||
NOPBT Margin | ||||||
Operating Taxes | 4,226 | (8) | 1,906 | |||
Tax Rate | ||||||
NOPAT | (221,821) | (117,148) | (110,155) | |||
Net income | (98,426) -9.60% | (108,874) 5.47% | (103,226) 47.93% | |||
Dividends | ||||||
Dividend yield | ||||||
Proceeds from repurchase of equity | 1,778 | 1,763 | 42,205 | |||
BB yield | -0.66% | -0.66% | -4.96% | |||
| Debt | ||||||
Debt current | 17,036 | 5,970 | 6,994 | |||
Long-term debt | 81,628 | 97,044 | 109,670 | |||
Deferred revenue | 268,115 | 304,000 | 322,730 | |||
Other long-term liabilities | (281,586) | 143 | ||||
Net debt | (135,393) | (244,492) | (39,358) | |||
| Cash flow | ||||||
Cash from operating activities | (118,106) | 193,612 | (50,250) | |||
CAPEX | (1,224) | (1,210) | (3,313) | |||
Cash from investing activities | 144,450 | (244,322) | 36,173 | |||
Cash from financing activities | 1,778 | 1,763 | 22,418 | |||
FCF | (215,336) | 153,109 | (367,477) | |||
| Balance | ||||||
Cash | 234,057 | 345,798 | 154,289 | |||
Long term investments | 1,708 | 1,733 | ||||
Excess cash | 232,349 | 346,545 | 155,956 | |||
Stockholders' equity | (472,386) | (377,120) | (264,262) | |||
Invested Capital | 716,902 | 451,153 | 742,338 | |||
ROIC | ||||||
ROCE | ||||||
| EV | ||||||
Common stock shares outstanding | 41,974 | 41,591 | 37,171 | |||
Price | 6.45 1.10% | 6.38 -72.10% | 22.87 12.83% | |||
Market cap | 270,735 2.03% | 265,353 -68.79% | 850,104 13.99% | |||
EV | 135,342 | 20,861 | 810,746 | |||
EBITDA | (214,144) | (113,835) | (105,022) | |||
EV/EBITDA | ||||||
Interest | 11,568 | 1,906 | ||||
Interest/NOPBT | ||||||